Single-cell deconvolution of 3,000 post-mortem brain samples for eQTL and GWAS dissection in mental disorders

07:20:49 PM, Jan 20, 2021

Authors

Yongjin Park^{1,2,3,8}, Liang He^{1,2,4,8}, Jose Davila-Velderrain^{1,2}, Lei Hou^{1,2}, Shahin Mohammadi^{1,2}, Hansruedi Mathys^{5,6}, Zhuyu Peng^{5,6}, David Bennett⁷, Li-Huei Tsai^{5,6}, Manolis Kellis^{1,2}

1. Computer Science and Artificial Intelligence Laboratory, Massachusetts Institute of Technology, Cambridge, MA, USA
2. Broad Institute of MIT and Harvard, Cambridge, MA, USA
3. Current affiliation: Department of Pathology and Laboratory Medicine, Department of Statistics, University of British Columbia, Vancouver, BC, Canada
4. Current affiliation: Biodemography of Aging Research Unit, Social Science Research Institute, Duke University, Durham, North Carolina, USA
5. Picower Institute for Learning and Memory
6. Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA
7. Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA
8. These authors contributed equally.

Contact:

- Yongjin Park: ypp@stat.ubc.ca
- Manolis Kellis: manoli@mit.edu

Abstract

Thousands of genetic variants acting in multiple cell types underlie complex disorders, yet most gene expression studies profile only bulk tissues, making it hard to resolve where genetic and non-genetic contributors act. This is particularly important for psychiatric and neurodegenerative disorders that impact multiple brain cell types with highly-distinct gene expression patterns and proportions. To address this challenge, we develop a new framework, SPLITR, that integrates single-nucleus and bulk RNA-seq data, enabling phenotype-aware deconvolution and correcting for systematic discrepancies between bulk and single-cell data. We deconvolved 3,387 post-mortem brain samples across 1,127 individuals and in multiple brain regions. We find that cell proportion varies across brain regions, individuals, disease status, and genotype, including genetic variants in TMEM106B that impact inhibitory neuron fraction and 4,757 cell-type-specific eQTLs. Our results demonstrate the power of jointly analyzing bulk and single-cell RNA-seq to provide insights into cell-type-specific mechanisms for complex brain disorders.

Introduction

The progression of most neurodegenerative and neuropsychiatric disorders, including Alzheimer’s disease (AD), commonly disrupts a broad spectrum of regulatory networks at the genomic and epigenomic levels, and poses a significant challenge to elucidating the mechanisms underlying the disease progression. In the genome-wide association studies (GWAS), AD is highly heritable, and most of the heritability is explained by common genetic variants. However, it is also highly polygenic, involving potentially hundreds of independent regulatory mechanisms.^{1–3} From the transcriptomic and epigenomic profiling of postmortem samples across different brain regions, we discover the target genes and regulatory elements perturbed by the disease progression and gain insights into the mechanisms of the genetic variants through the regulatory networks.^{3–5} However, many different factors contribute to the variability of the existing postmortem brain data, and it is crucially important to identify and classify these factors by information source.

A large part of the complexity in mental health traits stems from cell-type heterogeneity in brain tissues.⁶ Transcriptomic and epigenomic profiling at single cell-level resolution provides a principled tool with which to investigate the relationship between changes in cell-types and AD pathology. In our recent study, using single-cell RNA-seq (scRNA-seq) data across 80,660 nuclei isolated from post-mortem brain samples across 48 individuals, we discovered seven major types and 40 subtypes of the brain cells. We used these data to recognize cell-type-specific alterations associated with diverse pathological variables including age, sex, and AD pathology.⁶ However, single-cell RNA-seq profiling is often limited to a small number of individuals and optimized to yield a large number of cells. However, most single-cell studies, including our published scRNA-seq analysis,⁶ only involve at most tens of individuals:⁷ too few to measure correlations with other population-level variables such as genotype information. At the bulk tissue-level, however, RNA-seq studies routinely profile hundreds of individuals. For example, the Religious Orders Study and the Memory and Aging (ROSMAP) study has profiled bulk RNA-seq from more than 400 individuals with matched genotype information^{3,8}, and the Genotype-Tissue Expression consortium (GTEx) has profiled more than 2,500 brain samples across 13 brain regions from genotyped individuals.⁹

Here we develop a novel integrative framework to uncover cell-type-specific alterations of bulk samples, by combining both single-nucleus and bulk RNA-seq data with computational deconvolution followed by comprehensive association analysis. We develop a highly accurate deconvolution method which takes into account individual-level heterogeneity present in both single-nucleus and bulk data. We also directly address systematic discrepancies between single-nucleus and bulk data by characterizing substantial technical inconsistencies between them and developing a transformation approach to overcome them. We apply this method systematically across 3,387 samples to study the variation of neural cell-types across brain regions and their association with other variables measured in the bulk data. We then interrogate the mechanisms at the resolution of pathways and genetic regulatory networks by deconvolving the tissue-level eQTL models into cell-type-specific models.

Results

SPLITR deconvolution accounting for biological covariates and bulk-vs-single-cell differences.

Existing deconvolution methods^{10,11} estimate cell-type fractions from bulk RNA-seq data by making the explicit or implicit assumption that bulk RNA-seq data should match the sum of the same set of scRNA-seq data across the different cell types. In practice, however, aggregated scRNA-seq data and bulk RNA-seq data show substantial discrepancies, even for the most established marker genes. One reason for these discrepancies is that single-cell data and bulk data have highly distinct biases due to gene length, mRNA subcellular localization, transcriptional burstiness, mRNA stability, and the cell-to-cell variability of each gene’s expression patterns. This is most pronounced in single-nucleus RNA-seq datasets, as they only capture the nuclear component of each cell’s expression profile. Thus, aggregation of individual single-nucleus expression profiles is not expected to match bulk RNA-seq profiles that also capture the cytoplasmic

component of each gene’s expression levels. Systematic corrections are therefore required to relate single-cell datasets into bulk datasets, which are currently not known.

In addition, existing deconvolution methods typically use a single reference profile for each cell type.^{10,11} Such profiles are sometimes obtained by averaging multiple cells of the specific cell type,^{12–14} and other times by using a predicted developmental trajectory.¹⁵ However, biological variables such as disease status, age, or biological sex can substantially influence expressions of marker genes in both single-cell RNA-seq and bulk RNA-seq samples, making it inappropriate to use the same cell-type-specific reference expression profile for each individual. For example, the expression of several neuronal markers alters with age, sex, and disease status. Similarly, markers for nearly all cell types vary in their expression based on the phenotypic status of each individual. New methods are therefore needed which can tailor the cell-type-specific reference expression profiles used for each individual to their biological covariates.

To address these challenges, we developed a new deconvolution method, SPLITR (for Single-cell Phenotype-aware deconvolution across Individuals from Total RNA-seq), which explicitly models: (1) inter-individual variation in both bulk and cell-type-specific gene expression levels across biological covariates including age, biological sex, and disease status; and (2) platform-specific biases and differences between single-cell and bulk RNA-seq datasets, including differences in subcellular localization of each gene’s mRNA population in the nucleus/cytoplasm. We achieve this by executing the following three steps of model estimation.

In step 1 of the SPLITR method (Fig. 1a), we use reference single-cell datasets to establish marker genes and reference average expression levels for each target cell type. Here, we focus on brain cell types and use snRNA-seq profiles that our group previously generated across 80,000 cells from 48 individuals, clustered into seven cell types, consisting of excitatory neurons, inhibitory neurons, astrocytes, oligodendrocytes, oligodendrocyte progenitor cells (OPCs), microglia, and pericytes & endothelial cells.⁶ We used these clusters to define a set of 117 marker genes that were the most characteristic of each cell type, based on their differential cell-type-specific gene expression patterns (Supplementary Fig. 1), and confirmed these marker genes agreed with cell-sorted expression profiles¹⁶ and independent single-cell expression profiles.

In step 2 (Fig. 1b), we study the impacts of three phenotypic/biological covariates on cell-type-specific expression profiles. We use the cell-type-specific expression matrix (pseudo-bulk), created by taking average values over 80k cells across the 48 individuals within the seven cell types. We learn effects of the covariates by estimating a negative binomial model regressing cell-type-specific gene-vectors on the covariate and intercept terms. This modeling enables us to establish phenotype-aware adjustments to cell-type-specific expression patterns according to the phenotypic covariates of each individual whose bulk RNA-seq expression levels are to be deconvolved. For the application to Alzheimer’s Disease, we used age, sex, and pathological AD status, given their correlation with global gene expression changes in each major brain cell type.

In step 3 (Fig. 1c), we build a model that adjusts each marker gene’s bulk expression levels for experimental platform differences between scRNA-seq and bulk RNA-seq learn gene-specific correction terms. In particular, we find that scRNA-seq, and single-nucleus RNA-seq in particular, show gene-specific systematic differences stemming from each gene’s mRNA localization patterns, gene length, transcriptional burstiness, mRNA stability, cell-to-cell variability, and nuclear vs. cytoplasmic fractions. We assume the overall impact of such biases is shared across individuals (samples), and estimate the corresponding terms by leveraging control genes that show consistent expression patterns between the bulk and snRNA-seq data (see Online Methods for details).

In step 4 (Fig. 1d), we use these learned parameters to deconvolve the bulk expression profile by fitting a negative binomial regression of the bulk profile, adjusting for the learned phenotype-specific correction terms for each individual, and the platform-specific correction terms for each gene. For each cell type, we calculate an activity fraction estimate, corresponding to the number of transcripts produced by each cell, and a cell proportion estimate, correcting for the overall activity level of each cell type (Supplementary Fig. 3). In the case of brain, for example, we found that neuronal cells generate nearly four times more mRNA transcripts than glial cells, so their activity fraction estimates are approximately four times larger than their cell proportion estimates.

Deconvolution of 3,386 bulk samples and experimental validation of cell type proportions.

We used SPLITR to deconvolve a total of 3,386 bulk RNA-seq post-mortem brain samples, encompassing 15 brain regions from 1,127 individuals across three different studies (Fig. 2): (1) 482 dorsolateral prefrontal cortex (DLPFC) samples from the Religious Orders Study and Memory and Aging Project (ROSMAP) from Rush University^{3,17}; (2) 263 temporal cortex samples from the Mayo Clinic Brain Bank¹⁸, and (3) 2,642 samples across 13 brain regions in the Genotype-Tissue Expression (GTEx) data⁹.

Despite common discrepancies in the literature between different methods of estimating cellular proportions in brain samples¹⁹, we found that the resulting activity-corrected cell type fraction estimates were consistent with several previously-reported fractions from direct measurements. For example, the average cell count fractions estimated from the 482 dorsolateral prefrontal cortex samples in the ROSMAP cohort were 31% for neurons, 51% for glial cells, and 18% for vascular cells, consistent with previous estimates using the fractionator sampling method²⁰ and the isotropic fractionator²¹. Excitatory neurons were 4 times as abundant as inhibitory neurons, in line with previous reports²².

We also experimentally confirmed these cell type fractions using immunostaining in matched samples (Fig. 2c). Our SPLITR estimated of astrocytes were 18% of cells ($\pm 5\%$), consistent with our immunostaining-measured average of 18% across 8 ROSMAP samples. Even for microglia, which are both less abundant and smaller cells, thus biasing their abundance in some single-cell preparations, our SPLITR-based estimate of 9% ($\pm 5\%$) was consistent with our immunostaining-measured average of 10%.

The cell type proportion estimates sometimes differed from the counts of nuclei obtained for each cell type from the 10X protocol⁶, with the single-nucleus counts sometimes closer to our activity fraction estimates. This is likely due to experimental biases in earlier versions of the 10X protocol to more efficiently capture larger nuclei with more transcripts. For example, astrocytes, microglia, pericytes, and endothelial cells were under-represented in our 10X datasets, while excitatory neurons and oligodendrocytes were overrepresented compared to previous estimates. This indicates that SPLITR deconvolution can provide accurate estimates of cell type proportions, even when based on single-cell datasets with skewed proportions, as it is based on the expression patterns inferred from the single-cell datasets, rather than the cell proportions in those datasets.

Our estimated cell type proportions also captured known variability across different brain regions. For example, we found a substantially higher fraction of oligodendrocytes in hippocampus than frontal cortex (48% vs. 16% on average), more microglial cells in hippocampus than cortex (12% vs. 6% on average), and fewer neurons in hippocampus than in temporal cortex or in frontal cortex (15% vs. 21% vs. 42% on average).

Our estimates also captured cell type proportions vary across different cohorts associated with the different age ranges of the individuals profiled (Supplementary Tab. 1). Comparing the younger GTEx cohort (59 years old on average) with the older ROSMAP cohort (88 years old on average), we found that neurons decreased from 42% to 31% of cells, while glia increased from 38% to 50%, consistent with neuronal loss during aging.

We also compared the results of SPLITR with CIBERSORT¹⁰, using the same marker gene profiles (Supplementary Fig. 2). We found a general agreement for higher-abundance cell types, including excitatory neurons, oligodendrocytes, astrocytes, and microglia. However, for two of the cell types, CIBERSORT showed systematic problems, resulting in 0% estimates for inhibitory neurons for 68% of samples, and 0% estimate for oligodendrocyte progenitor cells for 79% of samples. Moreover, while SPLITR captured differences due to sex and age, CIBERSORT did not capture these subtle differences (Supplementary Fig. 2b-c).

Discovery of genetic variants influencing cell type proportion.

We first sought to recognize genetic variants that may underlie these cell type proportion differences between individuals. Treating the SPLITR-inferred proportions of each of the 7 cell types as a quantitative trait, we carried out a cell-fraction genome-wide association study (cfGWAS) to recognize genome-wide significant

and sub-threshold loci associated with cell type fraction (cfGWAS hits), which we define as single-nucleotide polymorphisms (SNPs) that govern cell type proportions. Using 403 ROSMAP individuals that have both genotype and RNA-seq data, we found several genome-wide significant ($P < 5e-8$) and sub-threshold ($P < 1e-5$) associations with cell type proportions.

The strongest association ($P = 6.4e-09$) was between reduced excitatory neuron fraction and >100 SNPs in the *TMEM106B* locus of chromosomal segment 7p21.3, including the A-to-G rs1990620 SNP (Fig. 3a). This locus is not previously-associated with AD, but it is associated with an AD-related neurodegenerative disease, frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP), and also with decreased-neuronal-fraction allele showing increased FTLD-TDP risk and decreased cognition in amyotrophic lateral sclerosis (ALS)²³⁻²⁶. Indeed, this association was not due to AD pathology in our cohort, and the cell-type-proportion association remained statistically significant after conditioning on the pathological phenotypic variables, such as the accumulation amyloid-beta and neurofibrillary tau (NFT) proteins, and pathological AD. These results suggest that the *TMEM106B* locus is an AD-independent contributor to cognitive decline, via decreased neuronal fraction.

Genotype-associated expression variation indicates that two nearby genes may mediate the *TMEM106B* locus genetic effect on neuronal fraction: the *TMEM106B* gene itself, a transmembrane gene involved in dendrite morphogenesis and the regulation of lysosomal trafficking, and *GRN*, an age-associated²⁷ essential gene involved in tau-negative FTLD²⁸ and lysosomal dysfunction during FTLD progression.²⁹ Both genes showed significantly-reduced tissue-level expression associated with the decreased-neuronal-fraction allele ($p < 3e-06$ and $p < 2e-03$, respectively), and previous studies indicate that *TMEM106B* interacts with *GRN*, and that rs1990620 may be the causal variant in this locus, via disruption of a CTCF binding motif that alters a topologically-associated domain and up-regulates *TMEM106B*³⁰. The associations were still significant when only including the controls ($p < 9e-04$ and $p < 1.5e-02$, respectively), and cell-type-specific eQTL analysis with cell-sorted and snRNA-seq data confirmed over-expression of *TMEM106B* in neurons, astrocytes, and oligodendrocytes, consistent with the previous reports^{31,32}.

Several additional subthreshold-level associations with excitatory neuron fraction were found overlapping known causal genes in neurodevelopmental processes, including: *ERBB4*, a risk gene for schizophrenia and a selective and functional marker gene for glutamatergic³³ and GABAergic synapses³⁴ in inhibitory neurons and interneurons; *DAOA* associated with schizophrenia in an Asian cohort³⁵; and *NPAS2*, conferring neuropsychiatric anxiety disorder and regulating GABAergic signal transmissions³⁶. While the main signal in the *TMEM106B* locus affects excitatory neurons, we found an additional genetic signal associated with both inhibitory neurons associated with rs1990620 ($P = 3.08e-6$). Lastly, we found an additional association with inhibitory neurons within the *TMEM106B* locus, with cfGWAS SNP rs4721064 ($p = 1.69e-06$), whose effect is independent and additive with that of rs1990620.

Deconvolved cell-type fractions are associated with increased risk for diverse phenotypes.

We found that changes in cell type fraction were also associated with increased risk for multiple traits, even when these were not directly measured in our cohort (Fig. 3c-d). For all 944 genotyped individuals across ROSMAP and GTEx, we used their complete genotype information across millions of common variants to calculate their genetic risk for a set of 56 traits (Supplementary Tab. 2), using polygenic risk score (PRS) estimates from GWAS summary statistics data (p-value threshold 0.01, with linkage disequilibrium decorrelation^{37,38} instead of pruning). A total of 17 traits showed nominal significance (p -value < 0.05), including Alzheimer's Disease and Crohn's disease.

We found several noteworthy examples (Fig. 3c-d): higher microglial fraction was associated with increased AD risk and increased body fat percentage, but decreased risk for type 2 diabetes (T2D) in ROSMAP; higher oligodendrocyte progenitor cell fraction was associated with increased risk of depression; higher pericyte and endothelial fractions was associated with increased risk of post-traumatic stress disorder (PTSD) and decreased risk of smoking; higher astrocyte fraction was associated with increased risk of depression and decreased risk of drinking; higher inhibitory neuron fraction was associated with higher cognitive performance

and lower schizophrenia risk; lastly, an increased oligodendrocyte fraction was associated with decreased risk of Inflammatory Bowel Disease (IBD).

Many traits associated with the same cell type showed only negligible correlation at the overall PRS level, indicating that our method can capture correlations not directly visible using only genetic information.

Cell-type fraction differences associated with Alzheimer’s pathology, biological sex, and age.

We next investigated whether cell type proportion changes were associated with phenotypic differences between individuals within the ROSMAP cohort, where phenotypic variables are readily available (Fig. 4).

We found that AD-related pathological variables were strongly associated with cell type proportion differences (Fig. 4c; Supplementary Fig. 4). Amyloid-beta deposition showed the strongest associations with fewer excitatory neurons ($P < 8e-5$), fewer inhibitory neurons ($P < 3e-3$), more oligodendrocytes ($P < 2e-6$), more astrocytes ($P < 3.8e-3$), and more pericytes/endothelial cells ($P < 1e-4$). Tau-protein deposition and loss of cognition also showed significant associations with fewer excitatory neurons and more oligodendrocytes.

We also found that cell type proportions were strongly associated with both biological sex and age (Fig. 4a-b). Male samples showed a higher fraction of excitatory neurons than female samples ($P < 0.004$, Wilcoxon rank-sum test) and a lower fraction of astrocytes ($P < 0.03$), oligodendrocyte progenitor cells ($P < .006$), and vascular cells ($P < 2e-5$) (Fig. 4a). In addition, older individuals (>100 years old) showed different cell type proportions than younger groups (<90 years old), with fewer excitatory neurons ($P < 0.008$), more astrocytes ($P < 0.003$), and fewer microglia ($P < 0.002$) (Fig. 4b).

These results indicate that our deconvolved cell type fractions successfully capture cell type proportion changes associated with phenotypic differences, even though only bulk samples were utilized for these analyses.

Cell-type-specific gene expression changes in AD show biologically-meaningful functional enrichments.

We found 2,470 genes with cell-type-specific changes associated with amyloid-beta, neurofibrillary tangles, and episodic memory decline in one of the seven cell types (Fig. 5a-b), using a generative model that captures the relationships between each gene’s transcript level with an interaction term of cell type and each pathological variable (age, sex, RIN scores, and other phenotypes). We controlled the FDR at 4.4% with the null distribution constructed by the Freedman-Lane permutation³⁹ of only one interaction term at a time while fixing all other correlated variables (Fig. 5a, Supplementary Fig. 5a). Only 12 of these 2,470 genes are among the 171 cell-type-marker genes.

These 2,470 genes showed highly cell-type-specific enrichment across 191 gene ontology (GO) terms (Fig. 5c) and 88 MSigDB⁴⁰ canonical pathways (Fig. 5d) ($FDR < 5\%$). Distinct enrichments were sometimes found for distinct AD phenotypes, between memory loss, neurofibrillary tangles, and amyloid-beta.

For example, genes with inhibitory-neuron-specific expression differences associated with AD pathology were enriched in intracellular transport (including endoplasmic reticulum) for memory-associated expression changes, and with mitochondrial biology for amyloid-associated changes. Genes with oligodendrocyte-specific expression differences associated with AD pathology were enriched in notochord development for memory-associated changes consistent with their roles in remyelination^{41,42} and with our single-cell analysis results⁶, and with mesenchymal differentiation for tangles-associated changes. Genes with microglia-specific expression differences in AD were enriched in synaptic plasticity⁴³ for neurofibrillary-tangles-associated expression changes, in mitochondrial functions for memory-associated expression changes, and fatty acid metabolism for amyloid-beta-associated expression changes. Genes with astrocyte-specific expression differences in AD were enriched in cytokines and secretion for amyloid-beta-related phenotypes, consistent with secretion of pro-inflammatory cytokines in astrocytes with the accumulation of amyloid-beta⁴⁴.

These results reveal a complex set of cell-type-specific alterations in diverse pathways associated with distinct phenotypic signatures of AD, provide important insights into the cellular and molecular changes in AD, and demonstrate SPLITER's ability to recognize cell-type-specific from bulk RNA expression.

Sparse Bayesian regression deconvolves tissue-level genetic effects into cell-type-specific eQTLs.

To help elucidate causal paths between genetic variation and complex brain disorders, we next sought to recognize genetic variants with cell-type-specific effects on brain gene expression, both at the bulk level and at the cell-type-specific level. For tissue-level eQTLs, we used our previously-described sparse Bayesian multivariate model⁴⁵, and for cell-type-level eQTLs we developed a new Bayesian eQTL deconvolution framework that models the observed bulk genetic effects as a mixture of cell-type-specific genetic effects, and infers a cell-type-specificity score (between 0 and 1) for each eQTL gene (eGene) in each cell type, corresponding to the probability with which this gene has cell-type-specific genetic effects for that cell type (Fig. 6a; Methods). To compare the performance of our deconvolved multivariate approach, termed deQTL, with other interaction QTL methods, we simulated realistic gene expression data, embedding a single causal cell type for each gene. We repeated our experiments on 121 randomly-selected linkage disequilibrium (LD) blocks, varying the level of expression heritability and number of causal eQTL variants (see Methods). In power analysis, our proposed approach clearly outperforms the other methods frequently used in cell-type interaction QTL analysis (Fig. 6b). Moreover, under the high heritability regime ($> 10\%$), the posterior probability of the deQTL model accurately distinguish causal cell types from the non-causal ones (Fig. 6c).

We applied this method to the 403 ROSMAP individuals that have both genotype information and gene expression information available. At the tissue level, we found a total of 5,586 eQTL genes (eGenes) with highly-heritable gene expression, associated with a total of 7,783 independent SNPs. At the cell-type-level, we found a total of 3,869 eGenes with cell-type-specificity score > 0.9 , associated with 4,757 independent SNPs. Approximately half of tissue-level eGenes ($N=2,687$, 48%) were also discovered at the cell-type level (Supplementary Fig. 5), enabling us to partition their genetic effects into the cell-types where they act.

A large fraction of cell-type-specific eGenes ($N=1,182$, 30%) were not discovered in our tissue-level analysis, indicating that our approach can discover high-confidence cell-type-specific eGenes even when these are not visible at the tissue level (Supplementary Tab. 3). For example, *DRD5* showed no genetic association at the tissue level, but individuals with the TT allele of rs6448858 (chr4:9595918) were in the top 40% of samples with highest excitatory neuron content, resulting in a high interaction term in our model, and a high cell-type-specificity score (Fig. 6d). Similarly, *ICA1* showed no tissue-level genetic effect, but individuals carrying the CC allele of rs6965329 (chr7:8161981) lay were among the 20% of samples with highest inhibitory neuron fractions (Fig. 6e).

Most cell-type-specific eGenes act in a single cell type ($N=3,133$, 81%), and a minority act in multiple cell types ($N=736$, 19%). Most act in inhibitory and excitatory neurons (61%), followed by oligodendrocytes ($n=710$), astrocytes ($n=588$), microglia ($n=364$), pericytes & endothelial cells ($n=319$), and oligodendrocyte progenitor cells ($n=24$) (Supplementary Tab. 1). For 872 cell-type-specific eGenes we found multiple independent eQTL variants, indicating more complex genetic control. Conversely, for 267 cell-type-specific eQTLs, we found multiple target eGenes, implicating gene-level pleiotropy.

Stratification of the GWAS polygenic risk score (PRS) models by the deconvolved eQTL annotations.

Lastly, we sought to recognize the cell types where disease-associated genetic variants exert their effect for diverse brain disorders, using genome-wide statistics for 56 neuronal, behavioral, psychiatric, and neurodegenerative traits (Supplementary Tab. 1). For each of the seven major cell types, we computed a PRS for each of the traits, using all nominally-significant ($P\text{-value} < 1e-2$) SNPs that lie within a ± 1 kb window of an

annotated cell-type-specific eQTL for that cell type (Fig. 7a). We then calculated the enrichment for each cell type by comparing the cell-type-specific PRS score to the PRS score obtained using all the SNPs.

Across all 1,682 individuals in the ROSMAP cohort⁴⁶, we found 15 GWAS traits that show significant cell-type-specific PRS scores across 19 cell types (FDR<10%), indicating that genetic variants in that trait preferentially act through cell-type-specific eQTLs in that cell type (Fig. 7b-c). For example, we find that microglial-specific eQTLs contribute disproportionately to the risk scores of AD², OCD (obsessive-compulsive disorder)^{47,48} and ASD (autism spectrum disorder)⁴⁹. Similarly, oligodendrocyte-specific eQTLs significantly enrich GWAS signals of osteoarthritis⁵⁰ and cognitive performance⁵¹. Pericyte and endothelial-specific eQTLs contribute disproportionately to increased risk of smoking⁵², UC (ulcerative colitis)⁵³, allergy⁵⁴, and depression and bipolar disorders⁵⁴.

The importance of microglial cells in AD is well-recognized^{55,56}, and several AD genes, such as BIN1⁵⁷ and MS4A4⁵⁸, are shown to act specifically in microglial cells. For ASD, the previous analysis showed male-specific over-expression of microglial marker genes in the cortex⁵⁹; for OCD, a mouse study showed that over-expression of NFKB/TNF-alpha pathways causally acts on relevant traits, such as excessive self-grooming behavior and hyperexcitability of the corresponding neurons⁶⁰.

Discussion

Understanding the mechanism of complex traits, including neurodegenerative disorders, has become a crucial component of prevention and treatment, yet remains a challenging and open problem. Part of the challenge stems from the complexity of the diseases at the cellular and molecular levels. A causal mechanism of complex traits is often manifested through multiple layers of genomic and epigenomic regulatory networks. The emerging technology of single-cell and single-nucleus sequencing provides unbiased profiling of cell types from a mixture of samples. Knowing the relevant cell-type context is a crucial step toward dissecting the complexity of diseases. Cell-type information enables biologically-informed Bayesian and causal inference, and improves experimental design in a matched cellular environment.

However, most single-cell-resolution profiling experiments cover a limited sample size and do not include the investigation of variation across individuals. On the other hand, while tissue-level bulk RNA-seq data fail to reach a cell-type resolution, they often carry a sufficiently large sample size. From richly-phenotyped bulk data, we can identify population-level associations of transcript measurements with other variables, such as genetic variants and phenotypes. Associations with small-effect variables are only made possible with a large cohort. Computational deconvolution methods, including SPLITR, abridge the gap between snRNA-seq and bulk RNA-seq data. We learn cell-type models from snRNA-seq and estimate cell-type fractions in the bulk data so that subsequent analysis can leverage a large sample size and rich phenotypic information.

Here, we present a highly calibrated deconvolution method, SPLITR, followed by a series of integrative studies with the variables in large-sampled bulk data. We identified cell-type-specific mechanisms of AD and other relevant disorders at the phenotype, demographic information, pathway, and genotype-level. Moreover, we characterized putative mechanisms, which may have impacted AD and other diseases, while pinpointing a molecular and pathway-level basis for understanding the comorbidity of complex neurodegenerative disorders. For instance, our results already suggest that microglial cells are a converging point of AD and neuropsychiatric disorders, such as OCD and ASD. Genetic markers in *TMEM106B* implicate potential pleiotropy between AD and FTLT in neuronal cells. Applying the same principle, we can investigate other neurodegenerative and neuropsychiatric disorders and even diseases in other domains, such as diabetes and cardiovascular disorders.

Materials and Methods

Preprocessing of the ROSMAP, Mayo, and GTEx RNA-seq data

We downloaded the ROSMAP RNA-seq data in the Dorsolateral Prefrontal Cortex (DLPFC) from Synapse (<https://www.synapse.org/#!Synapse:syn3388564>). We used gene-level expression data quantified by RSEM⁶¹, including a total of 55,889 coding and non-coding genes according to the GENCODE annotations (v19). The RNA-seq raw count data in the temporal cortex of 263 individuals from the Mayo RNA-seq project was downloaded from Synapse (<https://www.synapse.org/#!Synapse:syn3163039>). From the GTEx project (v8), we obtained gene-level count data in 13 brain regions, which will be made publicly available. We removed low-expressed genes (those genes for which fewer than three individuals had counts-per-million > 1) before normalization. We then normalized the RNA-seq raw counts using the trimmed mean of M-values normalization method⁶².

Definitions of an individual-specific deconvolution model

The ultimate goal of the deconvolution is to estimate the cell type fraction π_{ik} of each cell type k in an individual i , treating the selected marker genes as data points. In each bulk sample i , we fit the NB model by regressing the bulk profile vector $\mathbf{y}_i$ on the estimated cell type profile matrix $\hat{X}_i$, learned from snRNA-seq data.

We assume each gene-level quantification, Y (or Y_{gi} for a gene g on sample i), follows Negative Binomial (NB) distribution.⁶³ Namely, we define the data likelihood of Y with the mean μ and over-dispersion ϕ parameters:

$$\text{NB}(Y|\mu, \phi) \equiv \frac{\Gamma(Y + \phi^{-1})}{\Gamma(\phi^{-1})\Gamma(Y + 1)} \left(\frac{\mu}{\mu + \phi^{-1}} \right)^Y \left(\frac{\phi^{-1}}{\mu + \phi^{-1}} \right)^{\phi^{-1}}.$$

We define the NB model for the deconvolution problem:

$$P(Y_{gi}|\cdot) = \text{NB} \left(Y_{gi} \middle| \delta_g s_i \sum_{k=1}^7 \pi_{ik} \hat{X}_{gik}, \phi_g \right).$$

Here, we introduce auxiliary parameters, besides the π parameter:

- s_i : sample-specific bias term for each individual i (easily estimable)
- ϕ_g : over-dispersion parameter for each gene g (easily estimable)
- δ_g : gene-specific bias term for each gene g in the bulk data

As for the first two parameters, we simply replace the sampling bias s_i with the sequencing depth of the bulk sample and find a suitable gene-level dispersion parameter δ_g using an empirical Bayes method implemented in edgeR⁶³. However, finding a suitable δ value is non-trivial as this can be tightly dependent with π and is shared across all the samples. We discuss posterior inference algorithms in the next section.

Reference cell-type models with the sample-specific covariates adjusted (steps 1 and 2)

From the snRNA-seq profiling followed by clustering analysis⁶, we construct a cell type-specific marker gene expression matrix R_{gik} (of gene g , sample i , cell type k), including the 171 marker genes (~25 most differentially expressed in each cell type). Unlike conventional deconvolution methods^{10,11} that directly use

these marker gene profiles to estimate cell type fractions of bulk RNA-seq data, we adapt the cell type-specific marker gene model to the heterogeneity of biological and technical covariates.

We train each cell type k 's model by conducting the following NB regression model, $NB(R_{gik}|l_i\mu_{gik},\psi_g)$ across $i = 1, \dots, 48$ individuals, where l_i is the library size of sample i . We further specify the mean function μ_{gik} as: $\ln \mu_{gik} = \beta_{gk0} + \sum_{r=1}^3 \beta_{gkr} C_{ir}$ with the baseline activity β_{gk0} and the observed covariates C_{i1}, C_{i2}, C_{i3} correspond to the age, sex, and AD of an individual i , respectively.

We first estimate the overdispersion parameter ψ_g using DESeq2⁶⁴. We then estimate the NB regression parameters using Stan⁶⁵ and construct the adjusted reference panel for a new sample i by plugging in the trained model parameters, $\hat{X}_{gik} = \exp(\hat{\beta}_{gk0} + \sum_{r=1}^3 \hat{\beta}_{gkr} C_{ir})$. If all the coefficients (β) except the baseline were set to zero, our reference panel would be identical to the marker gene profiles used in the existing methods, but by including any non-zero effects of the known covariates, we prevent the marker genes from being influenced by these covariates in the subsequent deconvolution steps.

Learning gene-specific bias between the bulk and snRNA-seq (step 3)

In our preliminary experiments, a brute-force parametric estimation method that directly estimate the posterior distribution of the bias and the cell-type fraction parameters often yielded poor results, e.g., high variance. Instead, we estimate δ_g , assuming individual-level cell type fractions π_{ik} can be summarized average $\bar{\pi}_k$:

$$\prod_i \prod_{g=1}^{171} \text{NB} \left(Y_{gi} \middle| \delta_g s_i \sum_{k=1}^7 \bar{\pi}_k \hat{X}_{gik}, \phi_g \right).$$

To estimate the average $\bar{\pi}$, we leverage the subset of 69 ‘‘control’’ genes (Supplementary Fig. 1b, 1d) whose relative expression levels are robustly stable between the bulk RNA-seq and snRNA-seq data, and less variable across individuals:

$$\prod_i \prod_{g=1}^{69} \text{NB} \left(Y_{gi} \middle| \delta_g s_i \sum_{k=1}^7 \bar{\pi}_k \hat{X}_{gik}, \phi_g \right)$$

We optimize them in an EM algorithm by alternating between the two models: one for δ holding $\bar{\pi}$ fixed and the other for $\bar{\pi}$ fixing δ values.

Deconvolution to estimate the individual-specific cell type composition (step 4)

Provided that we have estimated auxiliary variables (δ , s , and ϕ) along with the parameters in the individual-specific reference cell type models (β), we resolve the individual-level cell type compositions (π_{ik}) in Bayesian inference using Stan⁶⁵.

Additional calibration step to compute the cell-level fraction estimates of cell types.

To convert the transcript-level cell type fraction estimates to the composition of actual cell counts, we need to adjust a differential level of transcript abundance per cell across different cell types. Using the average number of transcripts $\bar{x}_k$ per cell within each cell type k in the snRNA-seq data, we reverse-engineer the cell-level fraction (π') of each type that could have generated the estimate transcript-level fractions (π). We solve the following optimization for π' :

$$\min_{\pi'} \sum_{i=1}^n \left(\pi_{ik} - \bar{x}_k \pi'_{ik} / \sum_{j=1}^7 \bar{x}_j \pi'_{jk} \right)^2$$

subject to $\sum_{k=1}^7 \pi'_{ik} = 1$ for each i and $\pi'_{ik} > 0$.

Pathway enrichment

We measure the impact of cell-type fractions on downstream transcript levels at the pathway-level. Within each pathway, and for each cell type, we compute gene-level z-scores that estimate significance of covariance between the cell-type fraction and the genes in the pathway. Say that we construct a test statistic for a pathway with m genes on a cell type k : we first standardize the cell-type fraction scores p_{ik} (for individual $i = 1, \dots, n$, and cell type k) and gene expression x_{ig} (for an individual i and a gene g), and construct a gene-level score $z_{kg} = n^{-1/2} \sum_i p_{ik} x_{ig}$. Combining these, we have test statistic $m^{-1} \sum_g z_{kg}$ across m genes within each pathway. We estimate the null distribution by sample permutation along the individual axis.

Genotype data imputation

We collected genotypes of 672,266 SNPs in 1,709 individuals from the Religious Orders Study (ROS) and the Memory and Aging Project (MAP)⁴⁶ in the GWAS for detecting cfGWAS hits. We mapped hg18 coordinates of SNPs (Affymetrix GeneChip 6.0) to hg19 coordinates, matching strands using publicly available information

(http://www.well.ox.ac.uk/~wrayner/strand/GenomeWideSNP_6.na32-b37.strand.zip). We retained only those SNPs with MAF>0.05 and Hardy-Weinberg equilibrium (HWE) p-value>1e-04, computed based on 432 individuals who had all phenotype, genotype, and gene expression data. We imputed the genotypes by pre-phasing haplotypes based on the 1000 genome project⁶⁶ (phase I version 3) using SHAPEIT⁶⁷. We then imputed SNPs in 5MB windows using IMPUTE2⁶⁸ with 100 Markov Chain Monte Carlo iterations and 10 burn-in iterations and retained only SNPs with MAF> 0.05 and imputation quality score>0.6. For the Mayo RNA-Seq project, we used a genotype dataset imputed by the Michigan Imputation Server⁶⁹ with the Haplotype Reference Consortium (hrc.r1.1.2016) panel⁷⁰. The following documents provide more details about the Mayo dataset: <https://www.synapse.org/#!Synapse:syn8650955>.

Polygenic risk scores

We modeled the polygenic risk ρ_i of an individual i as a weighted average of scaled genotype information⁷¹: $\rho_i = \sum_j G_{ij} \theta_j$ where we take weighted average of genotype information G_{ij} (of individual i and SNP j) with the coefficients θ_j transferred from GWAS summary statistics data with the p-value threshold ($p < 0.01$) but the LD (linkage disequilibrium) structures decorrelated. Lacking individual-level phenotypes on all the available GWAS statistics, we fixed the p-value cutoff and the LD pruning steps were replaced with the decorrelation steps.^{37,38} However, fine-tuning these parameters will only improve the performance.

Sparse Bayesian regression to deconvolve tissue-level genetic effects into cell-type-specific eQTLs.

We designed the deconvolved eQTL (deQTL) model from the following Bayesian generative scheme:

- (1) For each genetic variant j and cell type k , we sample unique multivariate eQTL effect sizes $\theta_{jk} \sim$ a spike-slab prior.⁷² (2) Each cell type k generates expression variation across individuals by a linear model $\eta_{ik} = \sum_j G_{ij} \theta_{jk}$ on genetic information G_{ij} of each individual i in SNP j . (3) However, we only

observe bulk gene expression profile $\bar{Y}_i$ that is a mixture of cell type-specific genetic effects η_{ik} across the seven cell types, with some mixing proportion π_k (Fig. 6a). Provided that the estimate cell-type composition π is unbiased, we can model the mean of bulk profile as:

$$\mathbb{E}[\bar{Y}_i|G, \theta, \pi] = \sum_{k=1}^7 \pi_{ik} \left(\sum_{j=1}^p G_{ij} \theta_{jk} \lambda_k \right)$$

where we additionally include probabilistic loading factor $\lambda_k \in (0, 1)$.

If we estimate the deQTL model SNP by SNP and cell-type by cell-type ($p = 1$), this model simply resorts to an interaction eQTL model⁷³, testing non-zero-ness of the coefficient θ_k in $Y_i \sim \theta_{jk} \pi_{ik} \times G_{ij}$ without two singleton terms, which are π and G . In our multivariate model, we could include these non-interacting terms, but we only found such an over-parameterization was not as powerful as one might have expected. We concluded that these extra terms are rather unnecessary because these are likely to mediate the effect of cell-type-specific genetic variables by construction. It is widely accepted that effect size estimation of a causal path, while conditioning on an intermediate variable, can easily produce a biased result.⁷⁴

Simulation of bulk eQTL data using actual cell type composition and genotype matrix

We first select a causal cell type out of seven brain cell types where there are genetic effects on causal SNPs. In the Fig. 6b, we only show the results on the data simulated with three causal SNPs, but we varied the number of causal SNPs from 1 to 3. Our simulator generates gene expression data using the actual genotype matrix (G , standardized) and the deconvolved cell type estimations (π). We evaluated statistical power under the different level of total expression heritability (h^2), varying from 5% to 40%. Provided that there is one cell type (out of total $K=7$) genetically-regulated with three causal SNPs, our simulator generates convolved gene expression profiles in the following steps.

1. For each celltype $k \in [K]$ ($K=7$), if k is causal: we select three causal SNPs (j 's) uniformly at random and sample each genetic effect size $\theta_{jk} \sim \mathcal{N}(0, (K/3)^2)$. For non-causal SNPs, we simply let the effect size $\theta_{jk} = 0$. The deconvolved expression vector is constructed by a linear combination of the selected SNPs: $\mathbf{y}_k \sim G\theta_k\pi_k$.
2. For the rest of non-causal cell type $l \neq k$, we assign the expression vector $\mathbf{y}_l$ to non-genetic signals by sampling from isotropic standard Gaussian distribution, and combine them by taking a weighted linear combination, $\mathbf{y}_0 = \sum_{l \in \text{non-causal}} \mathbf{y}_l \pi_l$ except for the genetically regulated cell types.
3. We rescale $\mathbf{y}_0$ by multiplying a scaling factor to to achieve $\mathbb{V}[\mathbf{y}_0] = \mathbb{V}[\eta_g](1/h^2 - 1)$ to ensure that the simulated heritability to match with the assumed level, namely, $h^2 = \mathbb{V}[\eta_g]/(\mathbb{V}[\mathbf{y}_0] + \mathbb{V}[\eta_g])$.
4. The bulk RNA-seq data can be just a linear combination of these simulated celltype profiles: $\bar{Y} = \sum_{k=1}^K \mathbf{y}_k + \mathbf{y}_0$.

Competing deconvolved eQTL methods

We include comparison with other commonly used interaction QTL methods (Fig. 6):

- **deQTL** (this work): We fit multivariate deQTL model with stochastic variational Bayes inference algorithm. We then prioritize cell types in descending order of maximal posterior inclusion probability of genetic effects $\max_{j \in [p]} P(\theta_{jk} \neq 0 | \bar{Y}, \pi, G)$ for each cell type k .
- **deQTL** (this work with additional terms): We prioritize cell types by the same procedure as above (deQTL) except that we added extra (and unnecessary) non-interaction terms of genotypes and cell types.

- Interaction QTL: We estimate the full set of p-values for conventional interaction QTL analysis using `lm(y ~ cell type * genotype + cell type + genotype)` in R. We then summarize each cell type's score by minimum p-values across SNPs within each cell type. Prioritize the cell types in the ascending order of the minimal p-values.

Immunostaining validation of the predicted cell-type fractions

Fixed human brain tissue (prefrontal cortex, BA10) was sectioned at 50 μ m using a vibratome (Leica). The sections were boiled in IHC Antigen Retrieval Solution (ThermoFisher Scientific; catalog number 00-4955-58) containing 0.05% Tween-20 for 10 minutes and then placed in PBS for 20 minutes at room temperature. After washing with ddH₂O (three times 15 minutes) followed by one wash with PBS for 15 minutes, the brain sections were incubated in quenching solution (50mM ammonium acetate, 100mM CuSO₄) at room temperature overnight. After washing with ddH₂O (one wash for 15 minutes) and PBS (three times 15 minutes), the sections were permeabilized in PBS containing 0.3% Triton X-100 for 10 minutes and blocked in PBS containing 0.3% Triton X-100 and 5% normal donkey serum at room temperature for 2 h. The sections were incubated for 2 hours at room temperature in primary antibody in PBS with 0.3% Triton X-100 and 5% normal donkey serum. Primary antibodies were an anti-GFAP antibody (1:100; Abcam; ab53554, Goat polyclonal) and anti-Iba1 Antibody (1:500; Synaptic Systems; Cat. No. 234 004, Polyclonal Guinea pig antiserum). The sections were washed with PBS containing 0.3% Triton X-100 and 5% normal donkey serum at room temperature (four times 15 minutes) and then incubated with secondary antibodies (dilution 1:2000) for 2 hours at room temperature. Primary antibodies were visualized with Alexa-Fluor 488 and Alexa-Fluor 594 antibodies (Molecular Probes), and cell nuclei visualized with Hoechst 33342 (Sigma-Aldrich; 94403). The sections were washed with PBS containing 0.3% Triton X-100 and 5% normal donkey serum at room temperature (four times 15 minutes) and then mounted on Fisherbrand (TM) Superfrost (TM) Plus Microscope Slides in ProLong (TM) Gold Antifade Mountant. Images were acquired using a confocal microscope (LSM 710; Zeiss) with a 20x or 40x objective, and cell numbers were quantified using Imaris 8.3.1.

Figures

Figure 1.

Overview of our deconvolution method.

Figure 2.

Figure 2. Deconvolution of 3,386 tissue-level RNA-seq data across 15 brain regions reveals unique cell type compositions across different brain regions. Different colors indicate different cell types. (a) Average cell type fractions across different brain regions. (b) Population-level variation of cell type compositions in ROSMAP and Mayo cohorts. (c) The estimated cell type compositions are experimentally validated against the cell counts in microscopic images of neurons and microglial cells.

Figure 3.

Genetic variation across individuals induce markedly differential cell type compositions. (a) Genome-wide association studies of excitatory neuron fraction. X-axis: genomic location across 22 autosomes; y-axis: $-\log_{10}$ p-value of association effect sizes. (b) Genome-wide association studies of inhibitory neuron fraction. (c) Association of cell type fractions with the polygenic risk scores of 56 relevant traits. The boxes are scaled proportionally to association p-value (larger, more significant). The colors reflect the directionality of associations (blue for negative, yellow for positive). (d) Examples of the significant associations between cell types and GWAS traits at the polygenic risk score-level. X-axis: quantile of polygenic scores; y-axis: cell type fractions estimated from ROSMAP cohort.

a GWAS of excitatory neuron composition

b GWAS of inhibitory neuron composition

c

d

Figure 4.

Cell-type fractions in the brain samples dramatically change with known pathology and demographic variables. Y-axis: cell type composition; X-axis: pathological and demographic variables. (a) Cell type compositions change between female and male samples. X-axis: female vs male. (b) Cell type composition changes across different age groups. X-axis: age groups (years at death). (c) Cell type compositions as a function of pathological variables. X-axis: amyloid-beta (in square root).

Figure 5.

Figure 5. Cell-type-specific gene expressing changes in AD phenotypes show biologically-meaningful functional enrichment. (a) We estimated the null distribution (y-axis) for the posterior probability (x-axis) of non-zero cell-type-specific gene-level associations by Freedman-Lane permutation³⁹ (marked by “+”). Using them, we empirically calibrated the false discovery rate of the optimized posterior probabilities of genes (marked by solid dots). (b) Controlling FDR at 4.4% (posterior probability > 0.5), we found 2,470 genes are significantly associated in a cell-type-specific manner. The number in each circle accounts for the genes found associated with a different phenotype (the column) in a particular cell type. (c) Cell-type-specific gene ontology (biological process) enrichment results for the significantly-associated genes. X-axis: cell types; y-axis: keywords (gene sets). (d) Cell-type-specific pathway enrichment results for the significantly-associated genes.

Figure 6.

Deconvolved eQTL (deQTL) analysis dissects tissue-level genetic effects into the cell-type level mechanisms. (a) A schematic diagram for our deQTL method. π : cell type fraction estimated by the deconvolution step. G : genotype matrix. θ : cell-type-specific multivariate effect size. λ : cell-type loading. η : cell-type-specific genetic effect aggregated over multiple SNPs. (b) Power comparison with competing methods. Different colors and shapes mark different methods. X-axis: gene expression heritability in simulation. Y-axis: statistical power of causal cell type identification with empirical false discovery rate (FDR) controlled at 5%. (c) Our deQTL method separates causal cell types (thick lines) from non-causal ones (thin lines). Each panel, we simulate data assuming one causal cell type (the title of each panel). X-axis: gene expression heritability in simulation. Y-axis: the fraction of cell types discovered by the PIP cutoff > 0.5 . (d-e) Examples of the genes that are significantly regulated in the deQTL models, but fail to reach significance under a marginal eQTL model. X-axis: genotype of the lead SNP; y-axis: quantile-normalized gene expression. Total ROSMAP samples are partitioned by the cell type fractions. (d) A significant deQTL on *DRD5*. (e) A significant deQTL on *ICA1*.

a Train deQTL effect sizes θ and cell-type loading λ given cell type fraction π

b Power comparison (3 SNPs)

c

d DRD5 (Dopamine Receptor D5) expression partitioned by excitatory neuron fraction

e ICA1 (Islet Cell Autoantigen 1) expression partitioned by inhibitory neuron fraction

Figure 7.

Deconvolved eQTL SNPs partition heritability of GWAS summary statistics into 7 cell types. (a) A schematic diagram showing our approach to partition GWAS data by significant deQTL SNPs. We construct 7 PRS models, each of which is stratified by the cell-type-specific genomic regions. (b) We calibrate the significance of cell-type-specific enrichment by cell-type label permutation. (c) Summary of significant cell-type-specific deQTL SNPs. The boxes are scaled proportionally to association FDR (larger, more significant). The colors indicate different cell types. For those significant enrichments (FDR < 10%), we denote the percentage of genetic variance explained by deQTLs.

Tables

Table 1.

Polygenic risk scores significantly correlated with the estimated cell type fractions (p-value < 0.05).

GWAS	celltype	effect	p-value	q-value	ROSMAP	Mayo	GTEEx
Alzheimer Disease	microglia	2.749621	0.0059664	0.0417649	0.12 (1.4e-02)	0 (9.4e-01)	0.1 (9.4e-02)
Anger	astrocytes	-2.008674	0.0445717	0.3120018	-0.03 (5.7e-01)	-0.1 (1.3e-01)	-0.1 (9.9e-02)
Chron disease	oligodendrocyte progenitor cells	-2.763591	0.0057169	0.0400184	-0.05 (3.0e-01)	-0.08 (2.1e-01)	-0.09 (1.4e-01)
Depressed affect	astrocytes	-2.212236	0.0269504	0.0943262	-0.06 (2.7e-01)	-0.01 (8.3e-01)	-0.15 (1.2e-02)
Depressed affect	excitatory neurons	2.617282	0.0088633	0.0620432	0.04 (4.2e-01)	0.07 (2.6e-01)	0.15 (1.0e-02)
Eczema and dermatitis	microglia	-2.477348	0.0132363	0.0926538	-0.09 (9.5e-02)	0.01 (9.3e-01)	-0.13 (2.1e-02)
Educational attainment	microglia	1.969783	0.0488633	0.3345703	0.06 (2.6e-01)	0.05 (4.0e-01)	0.04 (5.0e-01)
Gastroesophageal reflux disease	excitatory neurons	2.063535	0.0390619	0.2734330	0.1 (3.8e-02)	0.07 (2.3e-01)	0 (9.4e-01)
Hypothyroidism / myxoedema	astrocytes	1.982280	0.0474479	0.1660676	0.04 (4.2e-01)	0.1 (1.2e-01)	0.12 (3.4e-02)
Hypothyroidism / myxoedema	oligodendrocyte progenitor cells	2.163069	0.0305358	0.1660676	0.06 (2.5e-01)	0.09 (1.3e-01)	0.07 (2.2e-01)
Obsessive compulsive disorder	excitatory neurons	-2.378993	0.0173600	0.0648418	-0.09 (9.1e-02)	-0.03 (6.5e-01)	-0.1 (1.0e-01)
Obsessive compulsive disorder	oligodendrocytes	2.354929	0.0185262	0.0648418	0.12 (2.4e-02)	0.03 (6.6e-01)	0.07 (2.5e-01)
Post-traumatic stress disorder	pericytes / endothelial cells	1.961637	0.0498048	0.3486334	0.08 (1.3e-01)	0.17 (6.2e-03)	0 (9.7e-01)
Type 2 diabetes BMI adjusted	microglia	-2.144866	0.0319636	0.2237450	-0.12 (1.4e-02)	0.03 (5.9e-01)	-0.05 (3.5e-01)
Ulcerative colitis	oligodendrocyte progenitor cells	-1.994747	0.0460705	0.3224934	-0.02 (6.2e-01)	-0.07 (2.7e-01)	-0.08 (1.6e-01)
Worry	pericytes / endothelial cells	-1.971289	0.0486908	0.3408359	-0.06 (2.2e-01)	-0.03 (6.6e-01)	-0.11 (6.2e-02)

Supplementary Figures

Supplementary Figure 1.

Average expression profiles of cell type marker genes in snRNA-seq data. (a) A total set of marker genes' average expression profiles in snRNA-seq data. (b) The average expression profiles of the control genes in snRNA-seq data. (c) There exists gene-length bias in the total set of marker genes. (d) We select the control genes to avoid the gene length bias.

Supplementary Figure 2.

Comparison with CIBERSORT. (a) We compared the performance of our cell-type deconvolution methods (SPLITR) with the other method (CIBERSORT¹⁰), providing the same maker gene profile matrix. (b) We highlight the difference between two methods in pericytes and microglia can be explained by sex (male vs. female) difference in the bulk data. (c) We highlight the difference between the two methods in pericytes and microglia can be explained by age difference in the bulk data.

Supplementary Figure 3.

Average cell type fractions estimated at cell-count-level.

Supplementary Figure 4.

Correlation between cell-type fractions in the brain samples with known pathological variables. Y-axis: cell type composition; X-axis: pathological variables. (a) X-axis: amyloid-beta (in square root). (b) X-axis: neurofibrillary tangles tau protein (in square root). (c) Cell type compositions change between AD and non-AD samples.

Supplementary Figure 5.

Empirically-calibrated false discovery rates of non-zero effects. (a) For the cell-type-specific gene models, we constructed the null data by Freedman-Lane permutation³⁹. X-axis: posterior probability cutoff; y-axis: false discovery rate. (b) For the deQTL models, we constructed the null data by permuting samples after adjusting non-genetic factors. X-axis: posterior probability cutoff; y-axis: density (log2 scaled).

Supplementary Figure 6.

Cell-type-specific gene ontology (cellular component) enrichment results for the significantly-associated genes. X-axis: cell types; y-axis: keywords (gene sets).

Supplementary Tables

Supplementary Table 1.

Summary of cell type deconvolution results

cohort	celltype	region	Mean(%)	SD(%)	N	Mean(cell,%)	SD(cell,%)
GTEEx	astrocytes	Amygdala	24.90	12.98	152	26.96	13.45
GTEEx	astrocytes	Anterior cingulate cortex (BA24)	11.92	8.80	176	17.60	10.36
GTEEx	astrocytes	Caudate (basal ganglia)	23.44	9.64	246	22.59	8.47
GTEEx	astrocytes	Cerebellar Hemisphere	33.48	7.61	215	52.78	7.44
GTEEx	astrocytes	Cerebellum	37.64	8.10	241	57.43	7.70
GTEEx	astrocytes	Cortex	9.24	6.27	255	13.74	7.09
GTEEx	astrocytes	Frontal Cortex (BA9)	11.00	9.04	209	15.90	9.96
GTEEx	astrocytes	Hippocampus	10.85	6.63	197	10.50	6.67
GTEEx	astrocytes	Hypothalamus	17.27	9.17	202	16.39	9.14
GTEEx	astrocytes	Nucleus accumbens (basal ganglia)	17.38	9.38	246	20.60	9.27
GTEEx	astrocytes	Putamen (basal ganglia)	16.00	8.12	205	14.27	6.94
GTEEx	astrocytes	Spinal cord (cervical c-1)	6.14	3.66	159	3.88	2.54
GTEEx	astrocytes	Substantia nigra	9.86	7.90	139	6.83	5.81
GTEEx	excitatory neurons	Amygdala	32.96	16.16	152	12.44	8.67
GTEEx	excitatory neurons	Anterior cingulate cortex (BA24)	57.24	16.72	176	31.51	14.46
GTEEx	excitatory neurons	Caudate (basal ganglia)	9.74	7.95	246	3.42	3.80
GTEEx	excitatory neurons	Cerebellar Hemisphere	48.77	7.33	215	24.63	5.63
GTEEx	excitatory neurons	Cerebellum	45.39	7.06	241	22.15	5.24
GTEEx	excitatory neurons	Cortex	63.12	13.75	255	33.46	12.88
GTEEx	excitatory neurons	Frontal Cortex (BA9)	62.14	18.02	209	34.17	15.36
GTEEx	excitatory neurons	Hippocampus	32.02	19.86	197	11.35	9.30
GTEEx	excitatory neurons	Hypothalamus	6.40	6.06	202	2.12	2.45
GTEEx	excitatory neurons	Nucleus accumbens (basal ganglia)	15.33	8.12	246	6.31	3.97
GTEEx	excitatory neurons	Putamen (basal ganglia)	7.67	6.95	205	2.45	2.67
GTEEx	excitatory neurons	Spinal cord (cervical c-1)	2.66	4.79	159	0.60	1.27
GTEEx	excitatory neurons	Substantia nigra	2.77	4.98	139	0.67	1.50
GTEEx	inhibitory neurons	Amygdala	7.75	4.72	152	5.42	3.94

(continued)

cohort	celltype	region	Mean(%)	SD(%)	N	Mean(cell,%)	SD(cell,%)
GTEEx	inhibitory neurons	Anterior cingulate cortex (BA24)	12.52	6.00	176	13.14	7.48
GTEEx	inhibitory neurons	Caudate (basal ganglia)	30.27	10.64	246	18.83	9.57
GTEEx	inhibitory neurons	Cerebellar Hemisphere	14.45	2.61	215	13.91	3.30
GTEEx	inhibitory neurons	Cerebellum	13.99	2.62	241	13.05	3.21
GTEEx	inhibitory neurons	Cortex	8.03	4.19	255	8.30	4.98
GTEEx	inhibitory neurons	Frontal Cortex (BA9)	6.96	3.93	209	7.44	4.79
GTEEx	inhibitory neurons	Hippocampus	5.31	5.14	197	3.52	4.04
GTEEx	inhibitory neurons	Hypothalamus	37.29	13.37	202	22.06	10.71
GTEEx	inhibitory neurons	Nucleus accumbens (basal ganglia)	46.74	10.26	246	35.25	11.76
GTEEx	inhibitory neurons	Putamen (basal ganglia)	30.46	10.77	205	17.31	8.24
GTEEx	inhibitory neurons	Spinal cord (cervical c-1)	2.80	4.28	159	1.16	2.03
GTEEx	inhibitory neurons	Substantia nigra	9.71	7.56	139	4.15	3.67
GTEEx	microglia	Amygdala	6.50	6.05	152	14.98	10.67
GTEEx	microglia	Anterior cingulate cortex (BA24)	2.14	2.94	176	6.75	6.49
GTEEx	microglia	Caudate (basal ganglia)	4.66	3.66	246	10.31	7.09
GTEEx	microglia	Cerebellar Hemisphere	0.98	1.42	215	3.47	4.01
GTEEx	microglia	Cerebellum	0.40	0.53	241	1.40	1.79
GTEEx	microglia	Cortex	1.69	1.79	255	5.75	4.88
GTEEx	microglia	Frontal Cortex (BA9)	2.02	3.77	209	6.15	7.70
GTEEx	microglia	Hippocampus	5.83	5.45	197	11.96	9.01
GTEEx	microglia	Hypothalamus	11.02	7.03	202	22.74	11.80
GTEEx	microglia	Nucleus accumbens (basal ganglia)	3.77	3.25	246	10.19	7.48
GTEEx	microglia	Putamen (basal ganglia)	3.91	2.78	205	8.18	5.34
GTEEx	microglia	Spinal cord (cervical c-1)	15.01	9.69	159	21.25	12.38
GTEEx	microglia	Substantia nigra	11.93	8.24	139	18.32	11.35
GTEEx	oligodendrocyte progenitor cells	Amygdala	6.39	3.68	152	5.51	2.80
GTEEx	oligodendrocyte progenitor cells	Anterior cingulate cortex (BA24)	4.04	3.41	176	4.72	2.96
GTEEx	oligodendrocyte progenitor cells	Caudate (basal ganglia)	4.56	2.49	246	3.58	1.75
GTEEx	oligodendrocyte progenitor cells	Cerebellar Hemisphere	0.38	0.36	215	0.49	0.43

(continued)

cohort	celltype	region	Mean(%)	SD(%)	N	Mean(cell,%)	SD(cell,%)
GTEEx	oligodendrocyte progenitor cells	Cerebellum	0.17	0.15	241	0.21	0.18
GTEEx	oligodendrocyte progenitor cells	Cortex	1.84	1.49	255	2.24	1.35
GTEEx	oligodendrocyte progenitor cells	Frontal Cortex (BA9)	2.64	2.02	209	3.20	1.76
GTEEx	oligodendrocyte progenitor cells	Hippocampus	3.33	2.32	197	2.57	1.79
GTEEx	oligodendrocyte progenitor cells	Hypothalamus	3.58	2.14	202	2.80	1.75
GTEEx	oligodendrocyte progenitor cells	Nucleus accumbens (basal ganglia)	2.89	1.95	246	2.80	1.63
GTEEx	oligodendrocyte progenitor cells	Putamen (basal ganglia)	2.58	1.81	205	1.89	1.29
GTEEx	oligodendrocyte progenitor cells	Spinal cord (cervical c-1)	2.75	1.78	159	1.43	0.99
GTEEx	oligodendrocyte progenitor cells	Substantia nigra	3.31	2.05	139	1.85	1.19
GTEEx	oligodendrocytes	Amygdala	14.87	9.74	152	24.93	13.10
GTEEx	oligodendrocytes	Anterior cingulate cortex (BA24)	4.81	7.34	176	10.59	11.24
GTEEx	oligodendrocytes	Caudate (basal ganglia)	17.59	8.98	246	27.47	11.40
GTEEx	oligodendrocytes	Cerebellar Hemisphere	0.78	0.99	215	2.02	2.40
GTEEx	oligodendrocytes	Cerebellum	1.06	1.20	241	2.70	2.89
GTEEx	oligodendrocytes	Cortex	7.81	8.11	255	18.27	13.66
GTEEx	oligodendrocytes	Frontal Cortex (BA9)	7.14	8.54	209	15.86	12.69
GTEEx	oligodendrocytes	Hippocampus	34.14	19.26	197	48.45	18.05
GTEEx	oligodendrocytes	Hypothalamus	14.07	12.09	202	19.89	13.98
GTEEx	oligodendrocytes	Nucleus accumbens (basal ganglia)	7.42	7.22	246	13.86	10.25
GTEEx	oligodendrocytes	Putamen (basal ganglia)	28.20	11.01	205	41.06	11.86
GTEEx	oligodendrocytes	Spinal cord (cervical c-1)	63.55	14.76	159	65.02	14.46
GTEEx	oligodendrocytes	Substantia nigra	49.49	14.50	139	54.92	13.97
GTEEx	pericytes / endothelial cells	Amygdala	6.63	6.87	152	9.75	7.08
GTEEx	pericytes / endothelial cells	Anterior cingulate cortex (BA24)	7.32	6.64	176	15.68	8.42
GTEEx	pericytes / endothelial cells	Caudate (basal ganglia)	9.74	5.08	246	13.80	5.87
GTEEx	pericytes / endothelial cells	Cerebellar Hemisphere	1.16	1.10	215	2.70	2.12
GTEEx	pericytes / endothelial cells	Cerebellum	1.36	1.15	241	3.06	2.31

(continued)

cohort	celltype	region	Mean(%)	SD(%)	N	Mean(cell,%)	SD(cell,%)
GTEEx	pericytes / endothelial cells	Cortex	8.27	5.85	255	18.25	8.41
GTEEx	pericytes / endothelial cells	Frontal Cortex (BA9)	8.10	6.06	209	17.29	7.35
GTEEx	pericytes / endothelial cells	Hippocampus	8.52	4.79	197	11.65	5.54
GTEEx	pericytes / endothelial cells	Hypothalamus	10.37	6.61	202	14.00	7.70
GTEEx	pericytes / endothelial cells	Nucleus accumbens (basal ganglia)	6.47	5.96	246	11.00	7.87
GTEEx	pericytes / endothelial cells	Putamen (basal ganglia)	11.18	5.93	205	14.84	6.58
GTEEx	pericytes / endothelial cells	Spinal cord (cervical c-1)	7.09	4.46	159	6.67	4.27
GTEEx	pericytes / endothelial cells	Substantia nigra	12.92	6.56	139	13.26	6.71
Mayo	astrocytes	Temporal Cortex	17.72	8.47	263	19.76	7.79
Mayo	excitatory neurons	Temporal Cortex	43.70	17.76	263	17.51	10.44
Mayo	inhibitory neurons	Temporal Cortex	3.76	3.06	263	3.01	2.97
Mayo	microglia	Temporal Cortex	3.21	3.87	263	7.98	6.11
Mayo	oligodendrocyte progenitor cells	Temporal Cortex	2.22	1.31	263	2.04	1.10
Mayo	oligodendrocyte progenitor cells	Temporal Cortex	20.74	13.51	263	35.74	16.45
Mayo	pericytes / endothelial cells	Temporal Cortex	8.64	5.17	263	13.96	6.24
ROSMAP	astrocytes	Dorsolateral Prefrontal Cortex	13.66	5.80	481	17.86	5.49
ROSMAP	excitatory neurons	Dorsolateral Prefrontal Cortex	55.13	11.92	481	24.67	9.56
ROSMAP	inhibitory neurons	Dorsolateral Prefrontal Cortex	7.00	2.43	481	5.98	2.85
ROSMAP	microglia	Dorsolateral Prefrontal Cortex	2.97	1.94	481	9.00	4.68
ROSMAP	oligodendrocyte progenitor cells	Dorsolateral Prefrontal Cortex	1.60	0.95	481	1.71	0.85
ROSMAP	oligodendrocytes	Dorsolateral Prefrontal Cortex	10.27	4.44	481	22.28	6.86
ROSMAP	pericytes / endothelial cells	Dorsolateral Prefrontal Cortex	9.38	3.74	481	18.49	4.64

Supplementary Table 2.

56 GWAS traits analyzed in this work

GWAS.traits	Source	N	Ncase	Ncontrol
Alzheimer Disease	Jansen (2018)	455,258	71,880	383,378
Anger	Watanabe (2018)	NA	NA	57,010
Annoyance	Watanabe (2018)	126,198	NA	NA
asthma	Watanabe (2018)	385,822	44,301	341,521
Atopic dermatitis	Paternoster (2011)	26,171	5,606	20,565
Attention-deficit/hyperactivity disorder	Demontis (2017)	53,293	19,099	34,194
Autism spectrum disorder	Weiner (2017)	46,350	18,381	27,969
Automobile speeding propensity	Karlsson Linner (2019)	404,291	NA	NA
Basal metabolic rate	Watanabe (2018)	379,821	NA	NA
Bipolar and depression	Watanabe (2018)	93,296	25,873	67,423
Bipolar disorder	Stahl (2017)	74,194	20,129	54,065
Body fat percentage	Watanabe (2018)	379,615	NA	NA
Body mass index	Yengo (2018)	700,000	NA	NA
Cholesterol medication	Watanabe (2018)	176,050	40,433	135,617
Chron disease	Franke (2010)	21,389	6,333	15,056
Cognitive performance	Lee (2018)	257,828	NA	NA
Depressed affect	Nagel (2018)	357,957	NA	NA
Depression	Watanabe (2018)	289,307	22,055	267,252
Diabetes	Watanabe (2018)	385,420	18,483	366,937
Drinks per week	Karlsson Linner (2019)	414,343	NA	NA
Eczema and dermatitis	Watanabe (2018)	9,381	279,476	289,307
Educational attainment	Lee (2018)	766,345	NA	NA
Ever smoker	Karlsson Linner (2019)	518,633	NA	NA
Extreme irritability	Watanabe (2018)	32,229	90,662	122,891
Gallstones	Watanabe (2018)	300,791	11,632	289,159
Gastritis and duodenitis	Watanabe (2018)	300,791	14,477	286,314
Gastroesophageal reflux disease	Watanabe (2018)	300,791	12,011	288,780
Hayfever / allergic rhinitis	Watanabe (2018)	289,307	22,057	267,250
Hayfever / allergic rhinitis / eczema	Watanabe (2018)	385,822	89,380	296,442
High blood pressure	Watanabe (2018)	385,699	103,381	282,318
High cholesterol	Watanabe (2018)	289,307	46,932	242,375
Hypothyroidism / myxoedema	Watanabe (2018)	289,307	18,740	270,567
Inflammatory bowel disease	Liu (2015)	96,486	9,846	86,640
Insomnia	Jansen (2019)	386,533	109,402	277,131
Irritability	Watanabe (2018)	369,232	104,545	264,687
Irritable argument	Watanabe (2018)	22,783	103,513	126,296
Major depressive disorder	Watanabe (2018)	244,890	10,402	234,488
Major depressive disorder	Ripke (2013)	173,005	59,851	113,154
Number of sexual partners	Karlsson Linner (2019)	370,711	NA	NA
Obsessive compulsive disorder	Stewart (2013) and Mattheisen (2015)	9,725	2,688	7,037
Osteoarthritis (meta)	Zengini (2018)	327,918	30,727	297,191
Osteoarthritis (UKB)	Watanabe (2018)	289,307	31,545	257,762
Osteoarthritis of hip	Watanabe (2018)	300,791	9,873	290,918
Osteoarthritis of knee	Watanabe (2018)	300,791	12,508	288,283
Post-traumatic stress disorder	Duncan (2017)	9,537	2,424	7,113
Rheumatoid arthritis	Okaba (2014)	103,638	29,880	73,758
Risk tolerance	Karlsson Linner (2019)	466,571	NA	NA
Schizophrenia	Ripke (2014)	87,491	33,426	54,065
Systemic lupus erythematosus	Bentham (2015)	23,210	7,219	15,991

The 1st PC of the four risky behaviors	Karlsson Linner (2019)	315,894	NA	NA
Traumatic depression	Watanabe (2018)	71,568	52,198	19,370
Type 2 diabetes (meta)	Mahajan (2018)	898,130	74,124	824,006
Type 2 diabetes (UKB)	Watanabe (2018)	244,890	16,673	228,217
Type 2 diabetes BMI adjusted	Mahajan (2018)	898,130	74,124	824,006
Ulcerative colitis	Anderson (2011)	26,405	6,687	19,718
Worry	Nagel (2018)	348,219	NA	NA

Supplementary Table 3.

Number of tissue-level eQTL and cell-type-specific deQTL SNPs and genes.

cell type	#eQTLs	#eQTLs cell-type only	#eQTLs cell-type only (%)	#genes	#genes cell-type only	#genes cell-type only (%)	color
brain tissue	7,783	0	0	5,586	0	0	#DDDDDD
cell-type combined	4,757	1,252	26	3,869	1,182	31	#FFCC00
inhibitory neurons	1,966	410	21	1,727	391	23	#389D34
excitatory neurons	1,259	239	19	1,071	230	21	#BDE29C
oligodendrocyte	710	228	32	692	229	33	#E01F25
astrocytes	588	147	25	556	147	26	#A8CEE1
microglia	364	176	48	357	173	48	#F89C9B
pericytes / endothelial cells	319	78	24	307	78	25	#FD7C21
oligodendrocyte progenitor cells	24	11	46	23	11	48	#FBBC74

References

1. Lambert, J. C. *et al.* Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease. *Nat. Genet.* **45**, 1452–1458 (2013).
2. Jansen, I. E. *et al.* Genome-wide meta-analysis identifies new loci and functional pathways influencing alzheimer’s disease risk. *Nat. Genet.* (2019).
3. Mostafavi, S. *et al.* A molecular network of the aging human brain provides insights into the pathology and cognitive decline of alzheimer’s disease. *Nat. Neurosci.* **21**, 811–819 (2018).
4. De Jager, P. L. *et al.* Alzheimer’s disease: early alterations in brain DNA methylation at ANK1, BIN1, RHBDF2 and other loci. *Nat. Neurosci.* **17**, 1156–1163 (2014).
5. Zhang, B. *et al.* Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer’s disease. *Cell* **153**, 707–720 (2013).
6. Mathys, H. *et al.* Single-cell transcriptomic analysis of alzheimer’s disease. *Nature* **570**, 332–337 (2019).
7. Lake, B. B. *et al.* Neuronal subtypes and diversity revealed by single-nucleus RNA sequencing of the human brain. *Science* **352**, 1586–1590 (2016).
8. Ng, B. *et al.* An xQTL map integrates the genetic architecture of the human brain’s transcriptome and epigenome. *Nat. Neurosci.* **20**, 1418–1426 (2017).
9. GTEx Consortium *et al.* Genetic effects on gene expression across human tissues. *Nature* **550**, 204–213 (2017).
10. Newman, A. M. *et al.* Robust enumeration of cell subsets from tissue expression profiles. *Nat. Methods* **12**, 453–457 (2015).
11. Aran, D., Hu, Z. & Butte, A. J. XCell: Digitally portraying the tissue cellular heterogeneity landscape. *Genome Biol.* **18**, 220 (2017).
12. Schelker, M. *et al.* Estimation of immune cell content in tumour tissue using single-cell RNA-seq data. *Nat. Commun.* **8**, 2032 (2017).
13. Tirosh, I. *et al.* Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. *Science* **352**, 189–196 (2016).
14. Trapnell, C. *et al.* The dynamics and regulators of cell fate decisions are revealed by pseudotemporal ordering of single cells. *Nat. Biotechnol.* **32**, 381–386 (2014).
15. Frishberg, A. *et al.* Cell composition analysis of bulk genomics using single-cell data. *Nat. Methods* **16**, 327–332 (2019).
16. Zhang, Y. *et al.* Purification and characterization of progenitor and mature human astrocytes reveals transcriptional and functional differences with mouse. *Neuron* **89**, 37–53 (2016).
17. Bennett, D. A. *et al.* The rush memory and aging project: Study design and baseline characteristics of the study cohort. *Neuroepidemiology* **25**, 163–175 (2005).
18. Allen, M. *et al.* Human whole genome genotype and transcriptome data for alzheimer’s and other neurodegenerative diseases. *Sci Data* **3**, 160089 (2016).
19. Bartheld, C. S. von, Bahnay, J. & Herculano-Houzel, S. The search for true numbers of neurons and glial cells in the human brain: A review of 150 years of cell counting. *J. Comp. Neurol.* **524**, 3865–3895 (2016).
20. Lyck, L. *et al.* An empirical analysis of the precision of estimating the numbers of neurons and glia in human neocortex using a fractionator-design with sub-sampling. *J. Neurosci. Methods* **182**, 143–156 (2009).
21. Andrade-Moraes, C. H. *et al.* Cell number changes in alzheimer’s disease relate to dementia, not to plaques and tangles. *Brain* **136**, 3738–3752 (2013).

22. Sahara, S., Yanagawa, Y., O'Leary, D. D. M. & Stevens, C. F. The fraction of cortical GABAergic neurons is constant from near the start of cortical neurogenesis to adulthood. *J. Neurosci.* **32**, 4755–4761 (2012).
23. Chen-Plotkin, A. S. *et al.* TMEM106B, the risk gene for frontotemporal dementia, is regulated by the microRNA-132/212 cluster and affects progranulin pathways. *J. Neurosci.* **32**, 11213–11227 (2012).
24. Van Deerlin, V. M. *et al.* Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. *Nat. Genet.* **42**, 234–239 (2010).
25. Vass, R. *et al.* Risk genotypes at TMEM106B are associated with cognitive impairment in amyotrophic lateral sclerosis. *Acta Neuropathol.* **121**, 373–380 (2011).
26. Zee, J. van der *et al.* TMEM106B is associated with frontotemporal lobar degeneration in a clinically diagnosed patient cohort. *Brain* **134**, 808–815 (2011).
27. Rhinn, H. & Abeliovich, A. Differential aging analysis in human cerebral cortex identifies variants in TMEM106B and GRN that regulate aging phenotypes. *Cell Syst* **4**, 404–415.e5 (2017).
28. Baker, M. *et al.* Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. *Nature* **442**, 916–919 (2006).
29. Zhou, X., Sun, L., Brady, O. A., Murphy, K. A. & Hu, F. Elevated TMEM106B levels exaggerate lipofuscin accumulation and lysosomal dysfunction in aged mice with progranulin deficiency. *Acta Neuropathol Commun* **5**, 9 (2017).
30. Gallagher, M. D. *et al.* A Dementia-Associated risk variant near TMEM106B alters chromatin architecture and gene expression. *Am. J. Hum. Genet.* **101**, 643–663 (2017).
31. Satoh, J.-I. *et al.* TMEM106B expression is reduced in alzheimer's disease brains. *Alzheimers. Res. Ther.* **6**, 17 (2014).
32. Busch, J. I. *et al.* Increased expression of the frontotemporal dementia risk factor TMEM106B causes c9orf72-dependent alterations in lysosomes. *Hum. Mol. Genet.* **25**, 2681–2697 (2016).
33. Vullhorst, D. *et al.* Selective expression of ErbB4 in interneurons, but not pyramidal cells, of the rodent hippocampus. *J. Neurosci.* **29**, 12255–12264 (2009).
34. Wen, L. *et al.* Neuregulin 1 regulates pyramidal neuron activity via ErbB4 in parvalbumin-positive interneurons. *Proc. Natl. Acad. Sci. U. S. A.* **107**, 1211–1216 (2010).
35. Chu, C.-S. *et al.* The DAOA gene is associated with schizophrenia in the taiwanese population. *Psychiatry Res.* **252**, 201–207 (2017).
36. Ozburn, A. R. *et al.* NPAS2 regulation of Anxiety-Like behavior and GABAA receptors. *Front. Mol. Neurosci.* **10**, 360 (2017).
37. Baker, E. *et al.* POLARIS: Polygenic LD-adjusted risk score approach for set-based analysis of GWAS data. *Genet. Epidemiol.* **42**, 366–377 (2018).
38. Chun, S. *et al.* Non-parametric polygenic risk prediction using partitioned GWAS summary statistics. *bioRxiv* (2019).
39. Freedman, D. & Lane, D. A Nonstochastic Interpretation of Reported Significance Levels. *J. Bus. Econ. Stat.* **1**, 292–298 (1983).
40. Liberzon, A. *et al.* Molecular signatures database (MSigDB) 3.0. *Bioinformatics* **27**, 1739–1740 (2011).
41. Jaramillo-Merchán, J. *et al.* Mesenchymal stromal-cell transplants induce oligodendrocyte progenitor migration and remyelination in a chronic demyelination model. *Cell Death Dis.* **4**, e779 (2013).
42. Rivera, F. J. *et al.* Aging restricts the ability of mesenchymal stem cells to promote the generation of oligodendrocytes during remyelination. *Glia* **67**, 1510–1525 (2019).

43. Rajendran, L. & Paolicelli, R. C. Microglia-Mediated synapse loss in alzheimer's disease. *J. Neurosci.* **38**, 2911–2919 (2018).
44. González-Reyes, R. E., Nava-Mesa, M. O., Vargas-Sánchez, K., Ariza-Salamanca, D. & Mora-Muñoz, L. Involvement of astrocytes in alzheimer's disease from a neuroinflammatory and oxidative stress perspective. *Front. Mol. Neurosci.* **10**, 427 (2017).
45. Park, Y. *et al.* A bayesian approach to mediation analysis predicts 206 causal target genes in alzheimer's disease. *bioRxiv* 219428 (2017).
46. De Jager, P. L. *et al.* A genome-wide scan for common variants affecting the rate of age-related cognitive decline. *Neurobiol. Aging* **33**, 1017.e1–1017.e15 (2012).
47. Stewart, S. E. *et al.* Genome-wide association study of obsessive-compulsive disorder. *Mol. Psychiatry* **18**, 788–798 (2013).
48. Mattheisen, M. *et al.* Genome-wide association study in obsessive-compulsive disorder: Results from the OCGAS. *Mol. Psychiatry* **20**, 337–344 (2015).
49. Weiner, D. J. *et al.* Polygenic transmission disequilibrium confirms that common and rare variation act additively to create risk for autism spectrum disorders. *Nat. Genet.* **49**, 978–985 (2017).
50. Zengini, E. *et al.* Genome-wide analyses using UK biobank data provide insights into the genetic architecture of osteoarthritis. *Nat. Genet.* **50**, 549–558 (2018).
51. Lee, J. J. *et al.* Gene discovery and polygenic prediction from a genome-wide association study of educational attainment in 1.1 million individuals. *Nat. Genet.* **50**, 1112–1121 (2018).
52. Karlsson Linnér, R. *et al.* Genome-wide association analyses of risk tolerance and risky behaviors in over 1 million individuals identify hundreds of loci and shared genetic influences. *Nat. Genet.* **51**, 245–257 (2019).
53. Anderson, C. A. *et al.* Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. *Nat. Genet.* **43**, 246–252 (2011).
54. Watanabe, K. *et al.* A global view of pleiotropy and genetic architecture in complex traits. *bioRxiv* (2018).
55. Zhang, B. *et al.* Integrated systems approach identifies genetic nodes and networks in late-onset alzheimer's disease. *Cell* **153**, 707–720 (2013).
56. Heppner, F. L., Ransohoff, R. M. & Becher, B. Immune attack: The role of inflammation in alzheimer disease. *Nat. Rev. Neurosci.* **16**, 358–372 (2015).
57. Crotti, A. *et al.* BIN1 favors the spreading of tau via extracellular vesicles. *Sci. Rep.* **9**, 9477 (2019).
58. Deming, Y. *et al.* The MS4A gene cluster is a key modulator of soluble TREM2 and alzheimer's disease risk. *Sci. Transl. Med.* **11**, (2019).
59. Werling, D. M., Parikshak, N. N. & Geschwind, D. H. Gene expression in human brain implicates sexually dimorphic pathways in autism spectrum disorders. *Nat. Commun.* **7**, 10717 (2016).
60. Krabbe, G. *et al.* Microglial NF κ B-TNF α hyperactivation induces obsessive-compulsive behavior in mouse models of progranulin-deficient frontotemporal dementia. *Proc. Natl. Acad. Sci. U. S. A.* **114**, 5029–5034 (2017).
61. Li, B. & Dewey, C. N. RSEM: Accurate transcript quantification from RNA-Seq data with or without a reference genome. *BMC Bioinformatics* **12**, 323 (2011).
62. Robinson, M. D. & Oshlack, A. A scaling normalization method for differential expression analysis of RNA-seq data. *Genome Biol.* **11**, R25 (2010).
63. Robinson, M. D. & Smyth, G. K. Small-sample estimation of negative binomial dispersion, with applications to SAGE data. *Biostatistics* **9**, 321–332 (2008).

64. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol.* **15**, 1–21 (2014).
65. Carpenter, B. *et al.* Stan: A probabilistic programming language. *J. Stat. Softw.* **76**, (2017).
66. The 1000 Genomes Project Consortium *et al.* A global reference for human genetic variation. *Nature* **526**, 68–74 (2015).
67. Delaneau, O., Marchini, J. & Zagury, J.-F. A linear complexity phasing method for thousands of genomes. *Nat. Methods* **9**, 179–181 (2012).
68. Howie, B., Fuchsberger, C., Stephens, M., Marchini, J. & Abecasis, G. R. Fast and accurate genotype imputation in genome-wide association studies through pre-phasing. *Nat. Genet.* **44**, 955–959 (2012).
69. Das, S. *et al.* Next-generation genotype imputation service and methods. *Nat. Genet.* **48**, 1284–1287 (2016).
70. McCarthy, S. *et al.* A reference panel of 64,976 haplotypes for genotype imputation. *Nat. Genet.* **48**, 1279–1283 (2016).
71. Chatterjee, N., Shi, J. & García-Closas, M. Developing and evaluating polygenic risk prediction models for stratified disease prevention. *Nat. Rev. Genet.* **17**, 392–406 (2016).
72. Mitchell, T. J. & Beauchamp, J. J. Bayesian variable selection in linear regression. *J. Am. Stat. Assoc.* **83**, 1023–1032 (1988).
73. Westra, H.-J. *et al.* Cell Specific eQTL Analysis without Sorting Cells. *PLoS Genet.* **11**, e1005223 EP (2015).
74. VanderWeele, T. J., Mumford, S. L. & Schisterman, E. F. Conditioning on intermediates in perinatal epidemiology. *Epidemiology* **23**, 1–9 (2012).